Mereo BioPharma
MREO
91 hedge funds and large institutions have $403M invested in Mereo BioPharma in 2024 Q4 according to their latest regulatory filings, with 21 funds opening new positions, 19 increasing their positions, 26 reducing their positions, and 7 closing their positions.
200% more first-time investments, than exits
New positions opened: 21 | Existing positions closed: 7
65% more call options, than puts
Call options by funds: $3.02M | Put options by funds: $1.84M
18% more funds holding
Funds holding: 77 → 91 (+14)
1.1% more ownership
Funds ownership: 13.75% → 14.85% (+1.1%)
7% less capital invested
Capital invested by funds: $435M → $403M (-$31.7M)
27% less repeat investments, than reductions
Existing positions increased: 19 | Existing positions reduced: 26
33% less funds holding in top 10
Funds holding in top 10: 3 → 2 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Janus Henderson Group
London,
|
+$18.8M |
| 2 |
UBS Group
Zurich,
Switzerland
|
+$10.4M |
| 3 |
Morgan Stanley
New York
|
+$4.74M |
| 4 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
+$4.52M |
| 5 |
UBS AM
Chicago,
Illinois
|
+$3.79M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$5.62M |
| 2 |
Adage Capital Partners
Boston,
Massachusetts
|
-$3.93M |
| 3 |
TC
Tejara Capital
London,
United Kingdom
|
-$2.02M |
| 4 |
ACP
Acuta Capital Partners
Redwood City,
California
|
-$1.89M |
| 5 |
6CM
683 Capital Management
New York
|
-$1.18M |
MREO Hedge Fund Activity: Q4 2024 in Review
91 of the 7,607 institutional investors tracked by Wall St. Rank reported a position in Mereo BioPharma (MREO) for Q4 2024, worth a combined $403M — down 7.3% from $435M a quarter earlier.
Buyers outnumbered sellers: 21 funds opened new MREO positions and 7 closed out — a net gain of 14 holders — while 19 added to existing stakes and 26 trimmed.
The largest buyer was Janus Henderson Group, adding an estimated $18.8M. The largest seller was Millennium Management, cutting an estimated $5.62M.
- 91 institutional investors held Mereo BioPharma (MREO) as of Q4 2024, up from 77 in Q3 2024.
- Funds reported $403M of Mereo BioPharma stock for Q4 2024, down 7.3% quarter-over-quarter.
- 21 funds opened new Mereo BioPharma positions in Q4 2024 and 7 closed out, a net change of +14 holders.
- The largest Mereo BioPharma buyer in Q4 2024 was Janus Henderson Group, an estimated $18.8M added.
- The largest Mereo BioPharma seller in Q4 2024 was Millennium Management, an estimated $5.62M sold.
Based on aggregated 13F filings for Q4 2024.